Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 57Carcinoma, Non-Small-Cell Lung 30Breast Neoplasms 26Neoplasms 24Neoplasm Metastasis 24Triple Negative Breast Neoplasms 21Parkinson Disease 4, Autosomal Dominant Lewy Body 10Lung Neoplasms 9Melanoma 8Stomach Neoplasms 7Carcinoma, Pancreatic Ductal 7Adenocarcinoma 7Ovarian Neoplasms 6Colorectal Neoplasms 6Squamous Cell Carcinoma of Head and Neck 4Esophageal Neoplasms 4Digestive System Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Recurrence 3Rectal Neoplasms 3Pancreatic Diseases 3Neoplasms by Site 3Lymphoma, Non-Hodgkin 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Endocrine Gland Neoplasms 3Digestive System Diseases 3

Interventions

pembrolizumab 3napabucasin 3Bevacizumab 3entinostat 2Paclitaxel 2Ocoxin 2Leucovorin 2Irinotecan 2Immunotherapy 2Gemcitabine 2Fluorouracil 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2vorasidenib 1sipuleucel-T 1pralsetinib 1palbociclib 1luprolide acetate gel depot 1linifanib 1lenvatinib 1interferon gamma-1b 1ficlatuzumab 1durvalumab 1catumaxomab 1Vaccines 1VB6-845 fusion protein 1Taxes 1Sorafenib 1Pemetrexed 1Papillomavirus Vaccines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms, Glandular and Epithelial × Albumin-Bound Paclitaxel × Clear all
NCT02993731 2023-11-15

CanStem111P

Sumitomo Pharma America, Inc.

Phase 3 Completed
1,134 enrolled 18 charts
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Diseases, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal

NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Sumitomo Pharma America, Inc.

Phase 1 Completed
7 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡